Oncology Institute, Inc.TOIEarnings & Financial Report
Nasdaq
TOI Q3 2025 Key Financial Metrics
Revenue
$136.6M
Gross Profit
N/A
Operating Profit
$-8.1M
Net Profit
$-16.5M
Gross Margin
N/A
Operating Margin
-5.9%
Net Margin
-12.1%
YoY Growth
36.7%
EPS
$-0.14
Financial Flow
Oncology Institute, Inc. Q3 2025 Financial Summary
Oncology Institute, Inc. reported revenue of $136.6M for Q3 2025, with a net profit of $-16.5M (-12.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $136.6M |
|---|---|
| Net Profit | $-16.5M |
| Gross Margin | N/A |
| Operating Margin | -5.9% |
| Report Period | Q3 2025 |
Oncology Institute, Inc. Annual Revenue by Year
Oncology Institute, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $393.4M).
| Year | Annual Revenue |
|---|---|
| 2024 | $393.4M |
| 2023 | $324.2M |
| 2022 | $252.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $85.8M | $94.7M | $98.6M | $99.9M | $100.3M | $104.4M | $119.8M | $136.6M |
| YoY Growth | 20.1% | 24.2% | 22.9% | 21.8% | 16.9% | 10.3% | 21.5% | 36.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $209.2M | $204.5M | $179.6M | $179.2M | $172.7M | $164.0M | $159.8M | $163.6M |
| Liabilities | $152.2M | $163.2M | $150.4M | $163.7M | $169.1M | $158.9M | $168.8M | $175.9M |
| Equity | $57.0M | $41.3M | $29.2M | $15.5M | $3.6M | $5.1M | $-9.0M | $-12.3M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-3.9M | $-15.9M | $-15.7M | $819000 | $4.2M | $-5.0M | $-10.2M | $-12.6M |